Scribeable vs Abridge:
Considering Abridge? Here is a factual look at how Scribeable differs — on pricing transparency, who owns the account, and the capital structure behind the platform.
120+ clinicians · 2,600+ notes generated — real counters, no composites (scribeable.ai/transparency)
Why Physicians Switch from Abridge
No published pricing — abridge.com routes every rate question to "Contact Us," so an individual clinician cannot see a price without a sales conversation
Sold as an enterprise health-system deployment, not an individual account — a solo or small-group physician cannot sign up directly
The account belongs to the health system's contract, not the clinician using it
Publish the Price or Don't
Abridge's own site offers no pricing page — only "Contact Us" and a login for existing customers. Scribeable publishes its rates: $39/month for Lite, $79/month for Pro, with a 14-day free trial and no credit card to start. You can see the price before you ever talk to anyone.
Who Holds the Account
Abridge's homepage cites 300+ health-system customers — Kaiser Permanente, Johns Hopkins, Duke Health, Mayo Clinic among them — and sells three platform experiences (clinicians, revenue cycle, nursing) into that enterprise relationship. The seat belongs to the health system's contract. A Scribeable account belongs to the clinician who signs up, and it moves with that clinician across every job they take.
A Bootstrapped Cap Table Is a Structural Fact, Not a Slogan
Abridge has raised roughly $780M across multiple rounds, most recently a $300M Series E led by Andreessen Horowitz and Khosla Ventures in June 2025. Scribeable has raised $0 in outside capital. That difference doesn't say anything about either company's intentions today — it says something about who each company answers to at the next board meeting.
Same Patient. Same Encounter.
See why physicians say Scribeable notes are “actually usable” — with integrated risk scores, billing codes, and clinical reasoning that typical AI scribes simply don’t generate.
HPI
62 y/o male presents with chest pain for 2 hours. Substernal, pressure-like, radiating to left arm. Associated with diaphoresis and shortness of breath. Pain started while climbing stairs. Patient has history of HTN, DM2, and hyperlipidemia. Takes lisinopril, metformin, and atorvastatin. Denies recent illness or trauma.
Assessment & Plan
*Note examples are illustrative representations based on common AI documentation patterns. “Typical AI Scribe” represents composite characteristics of standard tools and does not depict any specific product. Patient scenarios are entirely fictional. Clinical notes should always be reviewed by a licensed provider.
AI Medical Scribe Note Quality Comparison
Scribeable produces clinically enriched notes with integrated risk calculators (HEART Score, CHA₂DS₂-VASc, Wells PE, PHQ-9, Caprini VTE), automated billing code optimization (E&M levels, HCC/RAF capture, CPT codes), dangerous diagnosis exclusion documentation, evidence-based prescribing citations, CMS compliance for operative reports, HEDIS care gap tracking, and MIPS quality measure documentation. Typical AI scribes produce basic notes without these advanced clinical features.
ED Chest Pain: 62-year-old male presenting with substernal chest pressure, diaphoresis, and exertional dyspnea
HPI: 62 y/o male presents with 2 hours of substernal chest pressure, rated 8/10, radiating to left arm and jaw. Onset during exertion (climbing stairs). Associated with diaphoresis and exertional dyspnea. Pressure-like quality, unrelieved by rest. No pleuritic component, no positional variation, no reproducibility with palpation. Risk factors: HTN (10 years), DM2 (8 years), hyperlipidemia, 30-pack-year smoking history (quit 5 years ago), family history of MI (father at age 58). Current medications: lisinopril 20mg daily, metformin 1000mg BID, atorvastatin 40mg daily. Denies cocaine use, recent immobilization, or prior VTE.
Assessment & Plan: 1. Acute Chest Pain — High-risk presentation HEART Score: 7 (High Risk) - History: moderately suspicious (2), EKG: non-specific ST changes (1), Age: >65 (2), Risk factors: ≥3 (2), Troponin: pending initial (0) - Risk stratification: >12% 6-week MACE event rate → full ACS workup - Serial troponins q3h, 12-lead EKG (initial + repeat at 60 min) - ASA 325mg PO administered, heparin drip per ACS protocol - Cardiology consulted for probable cath lab activation Dangerous Diagnosis Exclusion: - STEMI: No ST elevation on initial EKG — serial monitoring - Aortic dissection: No tearing quality, no pulse differential, no mediastinal widening on CXR - PE: Low pretest probability (Wells PE: 1.5) — no immobilization, no prior VTE, no hemoptysis 2. Hypertension — BP 168/94 on arrival, improved to 142/88 post-NTG - Continue home lisinopril, recheck prior to disposition 3. DM2 — Glucose 186 on arrival - Hold metformin (contrast exposure risk), sliding scale insulin PRN
Cardiology Consult: 71-year-old female with new-onset atrial fibrillation and decompensated heart failure
HPI: 71 y/o female with known HFrEF (EF 35% on TTE 6 months ago), HTN, DM2, and CKD Stage 3a (baseline Cr 1.4), consulted for new-onset atrial fibrillation with RVR. Progressive exertional dyspnea (NYHA II → IV over 2 weeks), 3-pillow orthopnea (new), PND, and 4+ pitting edema to knees bilaterally. Weight gain of 8 lbs over 2 weeks. Triggers explored: dietary indiscretion (holiday meals), medication non-adherence (ran out of furosemide 10 days ago). No prior AF history, no palpitations previously. Denies chest pain, syncope, or presyncope.
Assessment & Plan: Reason for Consult: New-onset atrial fibrillation with RVR in setting of acute decompensated HFrEF. Requesting Service: Internal Medicine (Dr. Patel) 1. New-onset Atrial Fibrillation with RVR CHA₂DS₂-VASc Score: 5 (Female sex, age ≥75, HTN, DM, HF) - Stroke risk: 6.7%/year → strong anticoagulation indication - Rate control: avoid diltiazem (negative inotropy in HFrEF) → amiodarone 150mg IV bolus then 1mg/min × 6h - Anticoagulation: apixaban 5mg BID (preferred over warfarin given age + fall risk) - TEE prior to any cardioversion attempt if AF duration uncertain - HAS-BLED: 2 (HTN, age) — acceptable bleeding risk 2. Acute Decompensated Heart Failure (ADHF) NYHA Functional Class: IV (dyspnea at rest) - IV furosemide 80mg BID (2.5× home oral dose), net negative 1-1.5L/day - Carvedilol held (acute decompensation), restart when euvolemic - Add sacubitril/valsartan when stable (PARADIGM-HF indication: EF ≤40% on ACEi) - BNP trend: 1,840 → monitor for response to diuresis 3. CKD Stage 3a — Cr 1.4 (baseline), monitor with aggressive diuresis - KDIGO risk: moderate — monitor Cr/K daily with diuresis
Operative Note: Right total knee arthroplasty in 68-year-old male with severe tricompartmental osteoarthritis
Operative Note: Preoperative Diagnosis: Right knee severe tricompartmental osteoarthritis (Kellgren-Lawrence Grade IV) Postoperative Diagnosis: Same Procedure: Right total knee arthroplasty Surgeon: Dr. James Morrison (attending — present and scrubbed for entire case) Assistant: Dr. Chen (PGY-4) Anesthesia: Spinal with sedation (Dr. Rivera) Implants: Smith & Nephew Legion CR, Size 5 femoral / Size 4 tibial / 10mm poly insert EBL: 150 mL Tourniquet Time: 62 minutes (pneumatic, 275 mmHg) Specimens: Femoral and tibial bone cuts — to pathology Complications: None Findings: Severe tricompartmental degenerative changes with exposed subchondral bone medially, grade III chondromalacia laterally, intact PCL
Post-Operative Plan: 1. Weight Bearing: WBAT right LE with front-wheeled walker 2. DVT Prophylaxis: Enoxaparin 40mg SQ daily × 14 days + mechanical (SCDs while inpatient) 3. Pain: Multimodal — scheduled acetaminophen 1g Q6h, meloxicam 15mg daily, tramadol 50mg Q6h PRN (max 14 days) 4. Antibiotics: Ancef 2g IV × 24h post-op 5. PT: Initiate POD0 PM — CPM machine, active/passive ROM, gait training 6. Follow-up: 2 weeks (staple removal + wound check), 6 weeks (X-ray + ROM assessment) 7. VTE Risk: Caprini Score 7 (High Risk) — extended pharmacologic prophylaxis indicated
Primary Care: 55-year-old female Medicare Advantage patient with DM2, HTN, depression, and overdue preventive care
HPI: 55 y/o female Medicare Advantage patient presenting for chronic disease management follow-up. Last visit 3 months ago. Diabetes (DM2, 8 years): A1c 8.2% (up from 7.6%), reports adherence but dietary indiscretion during holidays. Home glucose logs show fasting 140-180 range. No hypoglycemic episodes. Denies polyuria, polydipsia, vision changes, or foot numbness. Last diabetic eye exam: 14 months ago (overdue). Last podiatry visit: never. Hypertension (12 years): Home BP readings averaging 135-145/85-90. Taking lisinopril 20mg daily consistently. Depression (MDD, recurrent): PHQ-9 score today: 14 (moderately severe). Persistent low mood, anhedonia, poor sleep (initial insomnia), decreased concentration. On sertraline 50mg × 6 months with partial response. Denies SI/HI, denies alcohol or substance use. Columbia Suicide Severity: negative for ideation and behavior.
Assessment & Plan: 1. DM2, Uncontrolled (A1c 8.2%) — HCC 19 - Add empagliflozin 10mg daily (SGLT2i — CV and renal benefit, EMPA-REG OUTCOME indication) - Continue metformin 500mg BID (not escalating given GI intolerance history) - Diabetic eye exam referral (overdue 2 months — HEDIS measure) - Podiatry referral for initial foot exam - Recheck A1c in 3 months, target <7% 2. Hypertension, Suboptimally Controlled — HCC (when with CKD/DM) - BP today 138/86 — above target of <130/80 (ACC/AHA for DM patients) - Increase lisinopril to 40mg daily - Home BP log review in 4 weeks 3. Major Depressive Disorder, Recurrent, Moderate — HCC 59 - PHQ-9: 14 (moderately severe) — partial response to sertraline 50mg - Increase sertraline to 100mg daily - Safety plan reviewed, crisis line provided (988) - Follow-up in 4 weeks, recheck PHQ-9 - If inadequate response → consider augmentation or psychiatry referral 4. Preventive Care Gaps Addressed: - Mammogram ordered (last: 26 months ago — HEDIS BCS measure) - Colonoscopy referral (age 55, average risk, never screened — HEDIS COL) - Tobacco screening: former smoker, quit 3 years — MIPS measure 226 - Annual flu vaccine administered today — MIPS measure 110
Feature-by-Feature Comparison
Pricing & Access
| Feature | Scribeable | Abridge |
|---|---|---|
| Published, self-serve pricingabridge.com has no pricing page; CTAs are "Contact Us" and "Log In" for existing customers | ||
| Sign up without a sales callAbridge is sold as an enterprise health-system deployment, not an individual signup | ||
| Free trial, no card requiredNo trial is advertised on abridge.com as of Jul 2026 |
Ownership & Capital
| Feature | Scribeable | Abridge |
|---|---|---|
| Clinician-owned, portable accountAbridge licenses seats to the health system, not the individual clinician | ||
| Zero outside capital (bootstrapped)Abridge raised a $300M Series E led by a16z and Khosla Ventures (Jun 2025); reported total funding ~$780M |
Clinical Intelligence
| Feature | Scribeable | Abridge |
|---|---|---|
| Deterministic clinical calculators (236, code-scored)Not stated on abridge.com as of Jul 2026 | ||
| Two-stage AI verification (draft + clarification pass)Not stated on abridge.com as of Jul 2026 |
Competitor facts on this page are sourced to each company's own public site and verified as of 2026-07-11; see page source for the full citation list. Competitor capabilities and pricing may change after that date.
Pricing Comparison
Abridge
Not published — enterprise contract, "Contact Us" only
Contact for pricing
Scribeable's rates are on the pricing page today. Abridge's public site has no pricing page and no self-serve tier; third-party estimates of enterprise contract value exist but are not confirmed by Abridge itself, so they are not repeated here.
Other AI scribes optimize for time to first draft. Scribeable optimizes for time to signed note, with a verification pass built in before you sign.
5.0 on the App Store120+
Clinicians on board
2,600+
Patient notes generated
Which Should You Choose?
Choose Abridge if you...
- Physicians at a health system that already runs an enterprise-wide Abridge deployment
- Organizations that specifically want Abridge's revenue-cycle and nursing platform experiences alongside clinician documentation
- Institutions with dedicated procurement and IT teams to manage an enterprise rollout
Frequently Asked Questions
Compare Other Alternatives
vs Dragon Copilot
Considering Microsoft Dragon Copilot, the product formerly sold as Nuance DAX? Here is a factual look at how Scribeable differs — on pricing transparency, who owns the account, and who each company answers to.
vs Nabla
Considering Nabla? Here is a factual look at how Scribeable differs — on pricing transparency, who owns the account, and the capital structure behind the "we don't train on your data" promise both companies make.
vs DeepScribe
Considering DeepScribe? Here is a factual look at how Scribeable differs — starting with the fact that DeepScribe's current public positioning is oncology-specific.
Start Your 14-Day Free Trial — No Credit Card
Compare Scribeable to Abridge on your own terms. Generate your first note in under 5 minutes.
Scribeable vs Abridge - AI Medical Scribe Comparison
Considering Abridge? Here is a factual look at how Scribeable differs — on pricing transparency, who owns the account, and the capital structure behind the platform.
Why Physicians Switch from Abridge
- No published pricing — abridge.com routes every rate question to "Contact Us," so an individual clinician cannot see a price without a sales conversation
- Sold as an enterprise health-system deployment, not an individual account — a solo or small-group physician cannot sign up directly
- The account belongs to the health system's contract, not the clinician using it
Why Choose Scribeable Over Abridge
- $39-79/month, published on the pricing page — no sales call required to see a rate
- Clinician-owned, portable account that moves with you across employers
- 236 clinical calculators, code-scored and validated, inside every note
- A two-stage AI pipeline: a draft pass, then a separate verification pass that asks a clarification question instead of guessing
- 14-day free trial (or 15 notes, whichever comes first), no credit card required
- Zero outside capital — bootstrapped, no VC fund with a future exit to plan around
Publish the Price or Don't
Abridge's own site offers no pricing page — only "Contact Us" and a login for existing customers. Scribeable publishes its rates: $39/month for Lite, $79/month for Pro, with a 14-day free trial and no credit card to start. You can see the price before you ever talk to anyone.
Who Holds the Account
Abridge's homepage cites 300+ health-system customers — Kaiser Permanente, Johns Hopkins, Duke Health, Mayo Clinic among them — and sells three platform experiences (clinicians, revenue cycle, nursing) into that enterprise relationship. The seat belongs to the health system's contract. A Scribeable account belongs to the clinician who signs up, and it moves with that clinician across every job they take.
A Bootstrapped Cap Table Is a Structural Fact, Not a Slogan
Abridge has raised roughly $780M across multiple rounds, most recently a $300M Series E led by Andreessen Horowitz and Khosla Ventures in June 2025. Scribeable has raised $0 in outside capital. That difference doesn't say anything about either company's intentions today — it says something about who each company answers to at the next board meeting.
Feature Comparison: Scribeable vs Abridge
Pricing & Access
| Feature | Scribeable | Abridge |
|---|---|---|
| Published, self-serve pricing | Yes | No |
| Sign up without a sales call | Yes | No |
| Free trial, no card required | Yes | Partial |
Ownership & Capital
| Feature | Scribeable | Abridge |
|---|---|---|
| Clinician-owned, portable account | Yes | No |
| Zero outside capital (bootstrapped) | Yes | No |
Clinical Intelligence
| Feature | Scribeable | Abridge |
|---|---|---|
| Deterministic clinical calculators (236, code-scored) | Yes | Partial |
| Two-stage AI verification (draft + clarification pass) | Yes | Partial |
Pricing Comparison
Scribeable: Free tier, then $39-79/month, published
Abridge: Not published — enterprise contract, "Contact Us" only
Scribeable's rates are on the pricing page today. Abridge's public site has no pricing page and no self-serve tier; third-party estimates of enterprise contract value exist but are not confirmed by Abridge itself, so they are not repeated here.
Which Should You Choose?
If pricing transparency, an account that stays yours across jobs, and a bootstrapped cap table matter to you, that's what Scribeable is built around. If your health system already runs an Abridge enterprise deployment across clinicians, revenue cycle, and nursing, that may be the more practical fit inside that organization.
Frequently Asked Questions
Does Abridge publish its pricing?
No. Abridge's website has no pricing page — the only conversion paths are "Contact Us" and a login for existing customers. Scribeable's pricing page lists $39/month (Lite) and $79/month (Pro) directly, no sales call required.
Can an individual physician sign up for Abridge?
Abridge is sold as an enterprise deployment to health systems — its own site describes 300+ health-system customers and names Kaiser Permanente, Johns Hopkins, Duke Health, and Mayo Clinic. There is no self-serve individual signup path on abridge.com. Scribeable is self-serve: an individual clinician can start a free trial directly.
Is Abridge VC-backed?
Yes. Abridge raised a $300M Series E led by Andreessen Horowitz and Khosla Ventures in June 2025 (source: Abridge's own blog post announcing the round), with total reported funding around $780M across its history. Scribeable has raised $0 in outside capital.
Can I use Scribeable if my hospital already uses Abridge?
Yes. Scribeable is a separate, clinician-owned account independent of any hospital contract. Physicians who use an employer-provided tool for hospital charting sometimes run Scribeable in parallel for documentation the employer's deployment doesn't cover.
Sources
Abridge's public site has no pricing page; CTAs are "Contact Us" and "Log In."
Abridge cites 300+ health-system customers, including Kaiser Permanente, Johns Hopkins Medicine, Duke Health, and Mayo Clinic.
Abridge raised a $300M Series E led by Andreessen Horowitz, with Khosla Ventures co-investing (June 2025).
Abridge's total funding is reported around $780M, at a $5.3B valuation following the Series E extension.
Scribeable pricing: Lite $39/mo, Pro $79/mo.
Explore More
Discover how Scribeable can help your practice with AI-powered clinical documentation